Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
Intel: Solid Results, But the Market Says "Not Enough"
Meta Platforms shares surge amid Jefferies 'Buy' recommendation 📈
US Open: Rebound attempt on Wall Street 📈Meta Platforms surges 3.5%
Stock of the Week: TSMC, the heart of the global AI revolution (January 22, 2026)